The co-occurrence of AR signaling and HER2 amplification, together with previously observed functional crosstalk between the AR and HER2 signaling pathways [52], point towards a therapeutic opportunity to combine AR inhibition with anti-HER2 therapy for better neutralization of oncogenic HER2 in AR-driven breast tumors. This evidence concerns the gene ERBB2 and breast neoplasm.